Navigation Links
Syndicom SpineConnect Web Platform Chosen for Applied Spine's Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System
Date:9/18/2007

Better collaboration and surgeon-to-surgeon communication leads to more

accurate clinical trial results in Stabilimax NZ study

DURANGO, Colo. and NEW HAVEN, Conn., Sept. 18 /PRNewswire/ -- Syndicom, the premier developer of collaborative innovation networks, today announced that the company is providing its SpineConnect platform to facilitate a clinical study for Applied Spine's Stabilimax NZ(R) Dynamic Spine Stabilization System. Stabilimax NZ is a medical device designed to provide stabilization of the lumbar spine in patients receiving decompression surgery for the treatment of spinal stenosis.

"Today's clinical trial landscape is littered with trials that fail to meet their planned timelines and patient accrual goals," said Thomas E. Wood, CEO of Applied Spine. "What has really surprised us is how Syndicom's technology has evolved like an ecosystem to support our changing needs during this clinical trial. I view it as a piece of soft clay that we can mold to fit our needs. The platform is flexible enough so that it can meet the expanding needs of our company."

Prior to partnering with Syndicom, Applied Spine faced a challenge familiar to medical device companies conducting clinical trials: Because the participating investigators are spread out across the United States in 20 sites, efficient communication between the parties is problematic. Typically Principal Investigators (PIs) collected the patient data submitted by the surgeon investigators and met one to two times a year to go through the patient cases post-operatively -- a highly inefficient process. Now for the first time, investigators from around the world can review all the trial cases in an organized, easily accessible, and thoroughly documented way to identify problems earlier and take corrective action sooner, thus reducing overall trial costs.

"Applied Spine and other leading medical device companies are under tremendous pressure to meet regulatory requirements, improve patient care, and reduce the time it takes to develop devices and take them to market," noted Scott Capdevielle, CEO of Syndicom. "We're pleased that Applied Spine is already achieving the benefits of online collaboration, and that they appreciate the value of unfettered communication to help meet these challenges."

Using Syndicom's platform, Applied Spine can run its clinical trial in a tightly controlled manner, which results in a higher quality study. That's because Syndicom SpineConnect allows investigating surgeons to proactively identify cases that strictly adhere to the protocols, post comments to cases, and learn from each others' experiences in a secure online environment.

"I love the technology, because it brings people from all over the world to the table to solve real-world problems in real time," said Richard Guyer, M.D., co-founder and fellowship director of the Texas Back Institute and a principal investigator in the Applied Spine study. "We have essentially become problem solvers with the other investigators, because we communicate all the time. We no longer have to wait up to a year to discuss the cases. Now it's instantaneous."

About Applied Spine Technologies, Inc.

Applied Spine Technologies, Inc., headquartered in New Haven, Conn., is developing Stabilimax NZ(R), a posterior dynamic stabilization device designed to support an injured or degenerated spine without eliminating motion. Stabilimax NZ is expected to offer numerous advantages over current spinal fixation products and even new artificial disc products-including a much less invasive and less traumatic implant procedure, maintenance of spine motion and disc function, and the potential to prevent or slow adjacent-level disc disease. For more information, visit http://www.appliedspine.com.

About Syndicom

Syndicom provides an array of Web-based tools that allow medical professionals, medical device manufacturers, and other professional communities to work together and solve problems in a timely, ef.cient and economical way. The company's set of proprietary collaborative technology products fosters the discovery of new treatment plans, more effective surgical techniques, and life-saving medical devices. Syndicom's advanced communication tools let physicians around the world share challenging patient cases and respond immediately to colleagues' questions. At the same time, Syndicom's innovative platform gives medical companies the ability to leverage and extend the knowledge and skills of physicians in the development of new medical technologies and devices. To learn more visit http://www.syndicom.com.

Contacts: Lee Graham Ronald Trahan, APR

(212) 333-4983 Ronald Trahan Associates, Inc.

leegraham@leegraham.biz 508-359-4005, x108


'/>"/>
SOURCE Syndicom
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
2. Materia Licenses Metathesis Catalyst Platform to Eisai
3. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
4. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
5. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
6. AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical Pipeline to Be Featured at AACR
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. Genetic Analysis Systems Enter the Clinical Mainstream
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
11. Sygnis Pharma AG announces date for presentation of clinical results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):